Drug Delivery Systems 4. Implants in Drug Delivery

In comparison with many of the other drug delivery systems, implantable pumps and implants for variable rate delivery are at a crude stage of development. Although exceptions exist, the typical implantable pump consists of an electromechanically complex mechanism to regulate drug delivery from a percutaneous refillable reservoir, while power to drive the system comes from a transcutaneous energy transmission system. The potential for electrical or mechanical failure is high, and the systems are not yet sufficiently convenient or easy to use to recommend in a routine therapy. Problems with refilling of an apparently well designed implanted reservoir have been observed while, at the same time, cutaneous energy transmission systems are not well established.

[1]  J. Urquhart,et al.  Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion , 1985, Brain Research.

[2]  F Theeuwes,et al.  Elementary osmotic pump. , 1975, Journal of pharmaceutical sciences.

[3]  H Nau,et al.  Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. , 1985, Toxicology and applied pharmacology.

[4]  R. Eaton,et al.  Implantation of an artificial pancreas. Current perspectives. , 1981, JAMA.

[5]  W. Kort,et al.  Superiority of continuous infusion of prednisolone over daily injections in the prolongation of heart allograft survival in rats. , 1982, Transplantation.

[6]  P. Blackshear,et al.  Control of Blood Glucose in Experimental Diabetes by Means of a Totally Implantable Insulin Infusion Device , 1979, Diabetes.

[7]  W. Spencer,et al.  A Review of Programmed Insulin Delivery Systems , 1981, IEEE Transactions on Biomedical Engineering.

[8]  H. Croxatto,et al.  Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants. , 1982, Acta endocrinologica.

[9]  B. Sikic,et al.  Improved therapeutic index of bleomycin when administered by continuous infusion in mice. , 1978, Cancer treatment reports.

[10]  R. Eaton,et al.  A remotely programmable insulin delivery system. Successful short-term implantation in man. , 1982, JAMA.

[11]  W. Hrushesky.  Circadian timing of cancer chemotherapy. , 1985, Science.

[12]  H. Gabelnick,et al.  Biodegradable systems for the sustained release of fertility-regulating agents. , 1979, Journal of steroid biochemistry.

[13]  I. Sivin,et al.  Three-year experience with NORPLANT subdermal contraception. , 1983, Fertility and sterility.

[14]  P. Blackshear,et al.  Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump , 1980, Cancer.

[15]  W. Karesh,et al.  Stimulating male sexual behavior with repetitive pulses of GnRH in female green iguanas, Iguana iguana , 1985 .

[16]  R. Wurtman,et al.  Artificial induction of melatonin rhythms by programmed microinfusion. , 1980, Neuroendocrinology.

[17]  P. Blackshear.  Implantable drug-delivery systems. , 1979, Scientific American.

[18]  R. Varco,et al.  Chronic heparin anticoagulant in dogs by continuous infusion with a totally implantable pump. , 1975, Transactions - American Society for Artificial Internal Organs.

[19]  P. Blackshear,et al.  Design and initial testing of a totally implantable transcutaneously controllable insulin delivery device. , 1978, Transactions - American Society for Artificial Internal Organs.

[20]  J. Soeldner.  Treatment of diabetes mellitus by devices. , 1981, The American journal of medicine.

[21]  B. Zinman,et al.  Present and Future Expectations Regarding Insulin Infusion Systems , 1981, Diabetes Care.

[22]  D. Lewis,et al.  Clinical evaluation of injectable biodegradable contraceptive system. , 1981, American journal of obstetrics and gynecology.

[23]  J. Anderson,et al.  The role of the fibrous capsule in the function of implanted drug-polymer sustained release systems. , 1981, Journal of biomedical materials research.

[24]  D. G. Allen,et al.  Insulin Delivery at Variable Rates from a Controlled Release Micropump , 1984 .

[25]  M Nałecz,et al.  Bioengineering aspects of the artificial pancreas. , 1978, Artificial organs.

[26]  H Buchwald,et al.  The design and initial testing of an implantable infusion pump. , 1972, Surgery, gynecology & obstetrics.

[27]  R. Langer,et al.  Magnetic modulation of release of macromolecules from polymers. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Urquhart,et al.  Rate-controlled delivery systems in drug and hormone research. , 1984, Annual review of pharmacology and toxicology.

[29]  H. Nau,et al.  A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. , 1981, Life sciences.

[30]  T. Cronan,et al.  Effects of chronically administered nicotine and saline on motor activity in rats , 1985, Pharmacology Biochemistry and Behavior.

[31]  R. Penn,et al.  Long-term intrathecal baclofen infusion for treatment of spasticity. , 1987, Journal of neurosurgery.

[32]  R. Penn.  Drug pumps for treatment of neurologic diseases and pain. , 1985, Neurologic clinics.

[33]  P. Blackshear,et al.  One year of continuous heparinization in the dog using a totally implantable infusion pump. , 1975, Surgery, gynecology & obstetrics.

[34]  P. Blackshear,et al.  A Totally Implantable Drug Infusion Defice: Laboratory and Clinical Experience Using a Model with Single Flow Rate and New Design for Modulated Insulin Infusion , 1980, Diabetes Care.

[35]  P. Blackshear,et al.  The implantable infusion pump: a new concept in drug delivery. , 1979, Medical progress through technology.

[36]  A. Albisser,et al.  Insulin delivery and the artificial beta cell: Luminal obstructions in capillary conduits , 1980, The International journal of artificial organs.

[37]  A NEW LOW-POWER HIGH-RELIABILITY INFUSION PUMP , 1979 .

[38]  R. Eaton,et al.  Future Therapy of the Insulin-dependent Diabetic Patient—The Implantable Insulin Delivery System , 1981, Diabetes Care.

[39]  D. Lewis,et al.  Poly(DL-lactide-co-glycolide)/norethisterone microcapsules: an injectable biodegradable contraceptive. , 1983, Biology of reproduction.

[40]  R. Penn,et al.  Cancer pain relief using chronic morphine infusion. Early experience with a programmable implanted drug pump. , 1984, Journal of neurosurgery.

[41]  R. Eaton,et al.  Some Engineering Aspects of Insulin Delivery Systems , 1980, Diabetes Care.

[42]  R. Leininger.  Polymers as surgical implants. , 1972, CRC critical reviews in bioengineering.

[43]  W. Buurman,et al.  LOCAL TREATMENT OF RENAL ALLOGRAFTS, A PROMISING WAY TO REDUCE THE DOSAGE OF IMMUNOSUPPRESSIVE DRUGS: COMPARISON OF VARIOUS WAYS OF ADMINISTERING PREDNISOLONE , 1986, Transplantation.

[44]  C. G. Pitt,et al.  The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels. , 1983, American journal of obstetrics and gynecology.

[45]  F Theeuwes,et al.  Dosage form index: an objective criterion for evaluation of controlled-release drug delivery systems. , 1977, Journal of pharmaceutical sciences.

[46]  A. Faúndes,et al.  First year clinical experience with six levonorgestrel rods as subdermal contraception. , 1979, Contraception.